Novo Nordisk A/S Class B NONOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NONOF is a good fit for your portfolio.
News
-
Novo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of Abating
-
Novo Holdings Set to Invest $200 Million in Quantum Technology
-
Novo Nordisk Probed by Senate Committee on Weight-Loss Drug Prices
-
Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500
-
Eight stock picks in AI, obesity drugs, -2-
-
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
-
This weight-loss ETF has performed well in its -2-
-
Ozempic, similar weight-loss drugs don't increase suicide risk: EU regulator
Trading Information
- Previous Close Price
- $129.77
- Day Range
- $125.00–131.25
- 52-Week Range
- $74.70–140.32
- Bid/Ask
- $123.30 / $130.96
- Market Cap
- $564.16 Bil
- Volume/Avg
- 1,124 / 36,595
Key Statistics
- Price/Earnings (Normalized)
- 46.81
- Price/Sales
- 16.86
- Dividend Yield (Trailing)
- 1.08%
- Dividend Yield (Forward)
- 0.21%
- Total Yield
- 1.84%
Company Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 60,000
- Website
- https://www.novonordisk.com
Competitors
Valuation
Metric
|
NONOF
|
LLY
|
SNY
|
---|---|---|---|
Price/Earnings (Normalized) | 46.81 | 83.07 | 10.98 |
Price/Book Value | 35.63 | 57.62 | 1.64 |
Price/Sales | 16.86 | 19.53 | 2.48 |
Price/Cash Flow | 32.33 | 81.16 | 12.24 |
Price/Earnings
NONOF
LLY
SNY
Financial Strength
Metric
|
NONOF
|
LLY
|
SNY
|
---|---|---|---|
Quick Ratio | 0.62 | 0.68 | 0.83 |
Current Ratio | 0.82 | 1.35 | 1.27 |
Interest Coverage | 192.15 | 14.11 | 8.40 |
Quick Ratio
NONOF
LLY
SNY
Profitability
Metric
|
NONOF
|
LLY
|
SNY
|
---|---|---|---|
Return on Assets (Normalized) | 30.82% | 11.20% | — |
Return on Equity (Normalized) | 94.27% | 57.69% | — |
Return on Invested Capital (Normalized) | 72.84% | 20.65% | — |
Return on Assets
NONOF
LLY
SNY
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wpghfngkm | Ctx | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vgkrdlqvh | Hthxns | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rmnpkdyf | Nwdnz | $99.6 Bil | |
MRNA
| Moderna Inc | Brzrkjhg | Vds | $42.7 Bil | |
ARGX
| argenx SE ADR | Xfyxgvpy | Jsh | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Pbmjnkf | Nhc | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qcwtckw | Gdghqd | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tvwkczgs | Wlxgkd | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Stxfrhsr | Mdpycs | $12.7 Bil | |
INCY
| Incyte Corp | Fcwkxffb | Rbcsyn | $11.9 Bil |